The company filed a material 8-K report with the SEC, so the model re-ran its full analysis. The rest of the picture is mixed, so the headline alone is not enough for a clear call.
Stocks › BTSG
Brightspring Health Services, Inc. (BTSG) stock analysis
BUY 48% confidence · analysed Oct 30, 2026
On Oct 30, 2026, our model rated Brightspring Health Services, Inc. (BTSG) BUY with 48% confidence at a price of $60.22. That means most of the technical, fundamental, money-flow and news signals point to upside.
Analysed price$60.22
Technical picture
The 14-day RSI is 35. Momentum is soft: below the neutral 50 line, but not yet oversold.
MACD is below its signal line, so short-term momentum is pointing down.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is 1.9x its 20-day average, so the latest move has real participation behind it.
Trend structure and money flow
Market structure: ranging / no clear structure.
The most recent swing high is $73.75 and the swing low is $30.64; traders often treat these as resistance and support.
Fundamentals
The company reports a profit margin of 2.5% and revenue growth of +23.0%.
In its latest quarter it earned $0.45 per share, which beat the $0.40 analysts expected, with revenue +23.0% year over year.
Wall Street's average rating is 1.2 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $78.94.
The next earnings report is expected around Oct 30, 2026; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $60.22, a target of $66.62 (+10.6%) and a stop-loss at $56.66 (-5.9%).
That is a reward-to-risk ratio of about 1.8 to 1: the potential gain is larger than the potential loss.
The plan has a time limit: reassess by Nov 20, 2026 whatever the price does.
Entry$60.22
Target$66.62
Stop-loss$56.66
Reassess byNov 20, 2026
Research notes
BrightSpring Health Services’ bull case rests on strong specialty/infusion pharmacy growth, expanding home-health volumes, operating leverage, and a record of repeated EPS beats; analysts generally rate the stock “Moderate Buy” with targets above its roughly $59 share price. The bear case is valuation and execution risk, including a projected roughly $45 million quarterly revenue hit from Inflation Reduction Act pressures, uneconomic-customer exits, slowing growth, and the possibility that elevated expectations are already priced in. The major recent catalyst is the company’s upcoming Q3 2026 earnings report, where consensus calls for about $3.86–$3.87 billion of revenue and $0.47–$0.49 adjusted EPS, potentially extending its seven-quarter EPS-beat streak. Shares have also recently moved above their 50-day average and are up strongly year to date, increasing both momentum and expectation risk.
The model's one-paragraph read
Leans BUY — composite score +0.48 (BUY). Technicals: RSI 35.01, MACD bearish, price above SMA50. Fundamentals: margin 2.5%, revenue growth 23.0%. Financial results: YoY revenue +23.0%, last EPS surprise +12.5%, next earnings 2026-10-30. Smart Money Concepts: ranging / no clear structure. FinGPT news read: positive. Internet research: BrightSpring Health Services’ bull case rests on strong specialty/infusion pharmacy growth, expanding home-health volumes, operating leverage, and a record of repeated EPS beats; analysts generally rate the stock “Moderate Buy” with targets above its roughly $59 share price. The bear case is valuation and execution risk, including a projected roughly $45 million quarterly revenue hit from Inflation Reduction Act pressures, uneconomic-customer exits, slowing growth, and the possibility that elevated expectations are already priced in. The major recent catalyst is the company’s upcoming Q3 2026 earnings report, where consensus calls for about $3.86–$3.87 billion of revenue and $0.47–$0.49 adjusted EPS, potentially extending its seven-quarter EPS-beat streak. Shares have also recently moved above their 50-day average and are up strongly year to date, increasing both momentum and expectation risk. Suggested levels: entry $60.22, target $66.62, stop-loss $56.66, exit by 2026-11-20 (21-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for BTSG
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 30, 2026 | BUY | 48% | $60.22 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on BTSG
Oct 30, 2026 · Brightspring Health Services, Inc. files an 8-K: earnings results
- Oct 30, 2026: BrightSpring Health Services, Inc. Reports Third Quarter 2026 Financial Results and Increases Full Year 2026 Guidance (GlobeNewswire)
Frequently asked questions
Is BTSG a buy right now?
As of Oct 30, 2026, our automated model rates Brightspring Health Services, Inc. (BTSG) BUY with 48% confidence: most of the technical, fundamental, money-flow and news signals point to upside. This is a model output for education, not personal investment advice.
What is the price target for BTSG?
The model's most recent plan targets $66.62 with a stop-loss at $56.66, from an entry near $60.22.
When does Brightspring Health Services, Inc. report earnings next?
The next earnings report is expected around Oct 30, 2026.
What does a BUY rating mean?
A BUY rating means most of the technical, fundamental, money-flow and news signals point to upside.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.